GlycoNet Investigator develops new chemistry to facilitate drug development and manufacturing

Posted: June 2, 2021

The collaborative project is partnered with CQDM, Simon Fraser University, Amgen, Merck, and Servier.

“We are delighted to continue our partnership with CQDM to advance Dr. Britton’s project,” said Elizabeth Nanak, Chief Executive Officer at GlycoNet. “This collaboration exemplifies how GlycoNet supports Canadian researchers while guiding translational projects along the innovation continuum to reach their commercialization potential. Such partnerships are essential to transform scientific breakthroughs into tangible benefits for Canadians.”

GlycoNet is delighted to announce that Network Investigator Dr. Robert Britton from Simon Fraser University has received a major multi-year investment from CQDM to develop novel carbohydrate-derived molecules to accelerate drug discovery and manufacturing. This project, partly supported by GlycoNet, is in partnership with three pharmaceutical companies: Amgen Canada, Merck Canada, and Servier Canada. Read the full announcement on CQDM’s news page.

Discover more from GlycoNet News.


Scroll to Top